FoundationOne (Tissue-Based) is Strongly Preferred Over Guardant360 for Glioblastoma Multiforme Post-Chemotherapy
For a patient with glioblastoma multiforme who has completed chemoradiation in the Philippines, FoundationOne CDx (tissue-based comprehensive genomic profiling) is the superior choice over Guardant360 (circulating tumor DNA assay), as blood-based ctDNA testing has critically limited sensitivity for detecting key glioblastoma mutations and cannot assess essential prognostic markers.
Why Tissue-Based Testing is Essential for Glioblastoma
Critical Limitations of Blood-Based ctDNA in Brain Tumors
The blood-brain barrier fundamentally limits the utility of plasma ctDNA testing in glioblastoma:
FoundationOne Liquid CDx detected the H3K27M mutation in only 2.8% of diffuse midline gliomas, while tissue-based FoundationOne CDx achieved 92.2% detection 1. This represents a 33-fold difference in sensitivity.
Blood-based testing also showed extremely poor detection of other critical GBM mutations: TP53 (2.8%), PDGFRA (0%), and NF1 (2.8%) 1.
The blood-brain barrier prevents adequate shedding of tumor DNA into peripheral circulation, making plasma ctDNA unreliable for CNS tumors 1.
What Tissue-Based Testing Provides for GBM
ESMO guidelines for high-grade glioma specifically mandate tissue-based molecular characterization 2:
- MGMT promoter methylation status - Predicts benefit from temozolomide chemotherapy (23 months median survival if methylated vs. 13 months if unmethylated) 2
- IDH mutation status - Critical prognostic marker per WHO classification 2
- 1p/19q co-deletion - Identifies oligodendroglial tumors with better prognosis 2
- EGFR amplification and EGFRvIII mutation - Potential therapeutic targets under investigation 2
- BRAF mutations - Found in 3-5% of GBM, potentially targetable 2
None of these essential markers can be reliably assessed through plasma ctDNA in glioblastoma patients.
Alternative: CSF-Based ctDNA (Not Plasma)
If tissue is truly unavailable or insufficient:
- Cerebrospinal fluid (CSF) ctDNA detected mutations in 67% of recurrent high-grade glioma patients 3, far superior to plasma testing
- CSF bypasses the blood-brain barrier limitation
- However, CSF sampling requires lumbar puncture and is not routinely performed 2
Practical Algorithm for the Philippines Context
First-Line Approach:
- Obtain adequate tissue at surgery or biopsy - This is mandatory per ESMO guidelines 2
- Send tissue for FoundationOne CDx if available and affordable
- Minimum essential testing if FoundationOne unavailable:
If Tissue Truly Insufficient:
- Do NOT use Guardant360 or other plasma ctDNA assays - sensitivity is inadequate 1
- Consider CSF sampling if clinically appropriate and patient has recurrent disease 3
- Prioritize repeat biopsy over plasma testing if treatment decisions depend on molecular results
Critical Caveats
- Guardant360 and similar plasma tests are designed for solid tumors with high ctDNA shedding (lung, colorectal, breast) 4, 5, 6, 7
- These platforms perform well in non-CNS cancers but should not be extrapolated to glioblastoma 1
- Tissue quantity matters: Even 1 mm³ of viable tissue is sufficient for diagnosis and molecular testing by experienced neuropathologists 8
- Store all resected tissue if storage capacity allows, as comprehensive profiling may require larger volumes 8
Cost and Access Considerations for the Philippines
While both tests are expensive:
- FoundationOne CDx provides actionable information for GBM treatment decisions (MGMT status guides temozolomide use) 2
- Guardant360 will likely yield non-informative results in GBM, wasting resources 1
- If cost is prohibitive, targeted testing for MGMT and IDH is more cost-effective than comprehensive profiling 2
The evidence unequivocally supports tissue-based testing for glioblastoma. Plasma ctDNA assays like Guardant360 lack the sensitivity to detect critical mutations in CNS tumors and should not be used for treatment decisions in GBM patients.